Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCTB41 Plus Docetaxel in Previously Treated Advanced NSCLC
NCT07609251Phase 2Not yet recruiting
- Sponsor
- Sinocelltech Group Limited
- Start
- May 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing SCTB41+docetaxel with Placebo+docetaxel (2 arms). Primary endpoint: Adverse Events at 24 months. Planned start May 2026; status: not yet recruiting.
02
Drugs
SCTB41
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07609251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07609251.